
Harnessing the power of IgE Technology
Epsilogen is developing novel IgE antibodies to treat cancer. The company’s lead candidate, MOv18 IgE, is in a Phase I clinical trial in folate receptor alpha positive cancer patients and is the world’s first IgE drug to enter clinical trials. Tim Wilson, CEO talks to Lu Rahman. Epsilogen was founded… Read More















